The application of visceral adiposity index in identifying type 2 diabetes risks based on a prospective cohort in China.
作者信息
Chen Chen, Xu Yan, Guo Zhi-rong, Yang Jie, Wu Ming, Hu Xiao-shu
机构信息
School of Public Health, Southeast University, Nanjing, Jiangsu 210009, China.
出版信息
Lipids Health Dis. 2014 Jul 8;13:108. doi: 10.1186/1476-511X-13-108.
BACKGROUND
Visceral adiposity index (VAI), a novel sex-specific index for visceral fat measurement, has been proposed recently. We evaluate the efficacy of VAI in identifying diabetes risk in Chinese people, and compare the predictive ability between VAI and other body fatness indices, i.e., waist circumference (WC), body mass index (BMI) and waist- to- height ratio (WHtR).
METHODS
Participants (n=3,461) were recruited from an ongoing cohort study in Jiangsu Province, China. Hazard ratio (HR) and corresponding 95% confidence interval (CI) between diabetes risk and different body fatness indices were evaluated by Cox proportional hazard regression model. Receiver operating characteristic (ROC) curve and area under curve (AUC) were applied to compare the ability of identifying diabetes risk between VAI, WC, WHtR and BMI.
RESULTS
A total number of 160 new diabetic cases occurred during the follow-up, with an incidence of 4.6%. Significant positive associations were observed for VAI with blood pressure, fasting plasma glucose, triglyceride, WC, BMI and WHtR. Moreover, increased VAI was observed to be associated with higher diabetes risk with a positive dose-response trend (p for trend<0.001). As compared to individuals with the lowest VAI, those who had the highest VAI were at 2.55-fold risk of diabetes (95% CI: 1.58-4.11). The largest AUC was observed for VAI, following by WC, WHtR and BMI.
CONCLUSIONS
VAI is positively associated with the risk of diabetes. Compared to other indices for body fatness measurements, VAI is a better and convenience surrogate marker for visceral adipose measurement and could be used in identifying the risk of diabetes in large-scale epidemiologic studies.
相似文献
BMC Cardiovasc Disord. 2020-3-5
High Blood Press Cardiovasc Prev. 2017-6
引用本文的文献
BMC Cardiovasc Disord. 2025-5-24
Front Endocrinol (Lausanne). 2025-2-21
J Clin Endocrinol Metab. 2024-9-16
Cardiovasc Diabetol. 2024-2-10
本文引用的文献
Appl Physiol Nutr Metab. 2013-7
Obesity (Silver Spring). 2013-4-13
Eur J Clin Invest. 2012-12-20
J Clin Endocrinol Metab. 2012-6-7